this is a great article for biotechs in Australia, or Melbourne in general
https://www. a f r.co m/work-and-careers/management/why-this-ceo-thinks-454pc-growth-in-his-company-is-just-the-beginning-20230526-p5dbih
The engagement of Dr. Ga briel Liberatore and Douglas Cubbin ( ex Telix top management) at OncoSil Medical appears to be an effort to replicate the success seen by companies like Telix Pharmaceuticals.
The article from the Australian Financial Review discusses the significant growth of Telix Pharmaceuticals, a Melbourne-based biotech company specializing in cancer treatment. Telix has topped the inaugural Financial Review Fast Global list, driven by its remarkable international revenue growth. This growth was catalyzed by a drug approval in the US. Between the financial years 2019-20 and 2021-22, Telix’s sales outside Australia surged from $5.2 million to an impressive $160 million, marking a 454% compound annual growth rate. This rapid growth exemplifies the potential for success in the biotech sector, particularly for companies like Telix Pharmaceuticals that achieve significant milestones such as drug approvals
By bringing in experts like Liberatore and Cubbin, OncoSil Medical may be positioning itself for similar success, leveraging their expertise and strategic insights in the biotech industry.
Telix Pharmaceuticals' success story, leading to its 454% growth, can be attributed to several strategic decisions and innovative developments:Innovative Technology
Telix's core technology develops molecules capable of carrying a radioactive particle for cancer detection and treatment. Their product Illuccix, used for prostate cancer diagnosis, acts as a radioactive beacon detectable via standard scans, offering precise imaging of cancer cells. This technology represents a more targeted and precise approach compared to traditional methods, capable of detecting and destroying cancer cells throughout the body.
Commercial Success
Illuccix's commercialization has had a significant impact, changing the lives of about 2000 patients globally every week. This represents the first commercial application of Telix's technology, with its ability to detect and address residual cancer post-prostatectomy without the need for hormone therapy. The product's success has been a key driver of Telix's revenue growth.
Global Expansion and Infrastructure
Despite the majority of Telix’s staff being based outside Australia, with most revenue also generated offshore, the company remains Australian-domiciled. Factors contributing to this include Australia’s R&D tax incentive scheme and the availability of medical isotopes. Telix has recently opened a $21 million nuclear medicine facility in Belgium, aiming to penetrate the European market, and has plans for manufacturing in Brisbane, Australia. Additionally, there are expansions into the Asian market, with approvals pending in China and Japan.
Future Growth Prospects
Telix is looking to expand its product range to include therapies for renal cancer and other types. The potential benefits of applying Telix’s technology to renal cancer diagnostics are profound, addressing misdiagnoses and unnecessary kidney removals. Telix's growth is expected to continue, backed by its rare status as a cashflow positive biotech company and the anticipated expansion of its product market.Telix Pharmaceuticals' strategic focus on innovative technology, successful commercialization, global expansion, and future growth prospects have collectively contributed to its exceptional growth and position in the biotech industry.
(20min delay)